MegaNano BioTech Inc.
Our goal is to develop the best immunotherapies for neurodegenerative disease and cancers including vaccines, antibodies.
Our US-based business is located in Tampa, Florida on the campus of the University of South Florida (USF Connect). We are operated by a group of researchers and scientists including cancer biologists, neuroscientists, chemists, and statisticians.
Sandwich ELISA kits quantitative detection:
Aβ40, and 42, alpha synuclein, and GPC1 protein; ELISA kits for cytokines
Dendritic cell vaccines for animal studies:
Aβ-amyloid based vaccine for Alzheimer’s disease and alpha synuclein-based vaccine for Parkinson’s disease.
Anti-Aβ (40, 42) antibodies, anti-Alpha Synuclein antibodies, anti-GPC1 antibodies, anti-HIV gp41 and gp120 antibodies
Nano-formula of CBD, melatonin, and coffee for oral and intranasal spray
The novelty of the patent
We have licensed a patent through USF: “an antigen stimulation dendritic cell vaccine”. It is a platform for immunotherapies, such as we can develop for cancer and neurological diseases.
The advantage of the dendritic vaccine can overcome aging-related immune tolerance and bridge the innate immunity and acquired immunity to control overreaction to a vaccine. Dendritic cell vaccines have been used in clinical trials for years and have shown no significant adverse effects.
Opportunities for Investment